[Form 4] Abbott Laboratories Insider Trading Activity
Abbott Laboratories (ABT) insider transaction: Philip P. Boudreau, Abbott's EVP and CFO, sold 387 common shares at $132.66 per share in a transaction recorded on 09/01/2025, reducing his direct holdings to 50,616 shares. He also reports indirect beneficial ownership of 363 shares held in a Profit Sharing Trust. The filing is signed by an attorney-in-fact on behalf of Mr. Boudreau.
Operazione interna di Abbott Laboratories (ABT): Philip P. Boudreau, EVP e CFO di Abbott, ha venduto 387 azioni ordinarie a $132,66 l'una in un'operazione registrata il 01/09/2025, riducendo la sua partecipazione diretta a 50.616 azioni. Segnala inoltre una proprietà beneficiaria indiretta di 363 azioni detenute in un Profit Sharing Trust. Il documento è firmato da un procuratore per conto del sig. Boudreau.
Transacción de insider en Abbott Laboratories (ABT): Philip P. Boudreau, EVP y CFO de Abbott, vendió 387 acciones comunes a $132,66 por acción en una operación registrada el 01/09/2025, reduciendo su tenencia directa a 50.616 acciones. También declara una propiedad beneficiaria indirecta de 363 acciones mantenidas en un Profit Sharing Trust. La presentación está firmada por un apoderado en nombre del Sr. Boudreau.
Abbott Laboratories(ABT) 내부 거래: Abbott의 EVP 겸 CFO인 Philip P. Boudreau는 2025-09-01에 기록된 거래에서 주당 $132.66에 보통주 387주를 매도하여 본인의 직접 보유 주식 수를 50,616주로 줄였습니다. 그는 또한 이익 공유 신탁(Profit Sharing Trust)에 보관된 363주에 대한 간접적 수익 소유권도 보고했습니다. 제출 서류는 Boudreau 씨를 대신해 법정대리인이 서명했습니다.
Transaction d'initié chez Abbott Laboratories (ABT) : Philip P. Boudreau, EVP et CFO d'Abbott, a vendu 387 actions ordinaires à 132,66 $ l'unité dans une opération enregistrée le 01/09/2025, réduisant sa participation directe à 50 616 actions. Il déclare également une propriété bénéficiaire indirecte de 363 actions détenues dans un Profit Sharing Trust. Le dossier est signé par un mandataire au nom de M. Boudreau.
Insider-Transaktion bei Abbott Laboratories (ABT): Philip P. Boudreau, EVR und CFO von Abbott, verkaufte in einer am 01.09.2025 verzeichneten Transaktion 387 Stammaktien zu je $132,66 und verringerte damit seine direkte Beteiligung auf 50.616 Aktien. Er meldet außerdem eine indirekte wirtschaftliche Eigentümerschaft von 363 Aktien, die in einem Profit Sharing Trust gehalten werden. Die Einreichung ist von einem Bevollmächtigten im Namen von Herrn Boudreau unterzeichnet.
- Reporting is complete and compliant with Section 16 requirements, including transaction code and holdings after the sale.
- Substantial retained direct ownership of 50,616 shares indicates continued alignment with shareholders.
- Insider sold 387 shares, a disposition that reduced direct holdings (sale price reported at $132.66 per share).
Insights
TL;DR: Small, routine insider sale; remaining direct holdings remain material for alignment with shareholders.
This sale of 387 shares represents a de minimis disposition relative to total direct holdings of 50,616 shares, suggesting the transaction is likely a routine liquidity event rather than a change in confidence in the company. The report also notes a small indirect holding in a Profit Sharing Trust. No derivative transactions or other material changes to compensation structure are disclosed.
TL;DR: Disclosure is complete and follows Section 16 reporting norms; transaction size is immaterial to governance stance.
The Form 4 identifies the reporting person, relationship to the issuer, transaction code and price, and residual holdings, and includes an explanatory note about the trust balance. The signature is provided via attorney-in-fact as permitted. There are no indications of coordinated sales, option exercises, or other governance events in this filing.
Operazione interna di Abbott Laboratories (ABT): Philip P. Boudreau, EVP e CFO di Abbott, ha venduto 387 azioni ordinarie a $132,66 l'una in un'operazione registrata il 01/09/2025, riducendo la sua partecipazione diretta a 50.616 azioni. Segnala inoltre una proprietà beneficiaria indiretta di 363 azioni detenute in un Profit Sharing Trust. Il documento è firmato da un procuratore per conto del sig. Boudreau.
Transacción de insider en Abbott Laboratories (ABT): Philip P. Boudreau, EVP y CFO de Abbott, vendió 387 acciones comunes a $132,66 por acción en una operación registrada el 01/09/2025, reduciendo su tenencia directa a 50.616 acciones. También declara una propiedad beneficiaria indirecta de 363 acciones mantenidas en un Profit Sharing Trust. La presentación está firmada por un apoderado en nombre del Sr. Boudreau.
Abbott Laboratories(ABT) 내부 거래: Abbott의 EVP 겸 CFO인 Philip P. Boudreau는 2025-09-01에 기록된 거래에서 주당 $132.66에 보통주 387주를 매도하여 본인의 직접 보유 주식 수를 50,616주로 줄였습니다. 그는 또한 이익 공유 신탁(Profit Sharing Trust)에 보관된 363주에 대한 간접적 수익 소유권도 보고했습니다. 제출 서류는 Boudreau 씨를 대신해 법정대리인이 서명했습니다.
Transaction d'initié chez Abbott Laboratories (ABT) : Philip P. Boudreau, EVP et CFO d'Abbott, a vendu 387 actions ordinaires à 132,66 $ l'unité dans une opération enregistrée le 01/09/2025, réduisant sa participation directe à 50 616 actions. Il déclare également une propriété bénéficiaire indirecte de 363 actions détenues dans un Profit Sharing Trust. Le dossier est signé par un mandataire au nom de M. Boudreau.
Insider-Transaktion bei Abbott Laboratories (ABT): Philip P. Boudreau, EVR und CFO von Abbott, verkaufte in einer am 01.09.2025 verzeichneten Transaktion 387 Stammaktien zu je $132,66 und verringerte damit seine direkte Beteiligung auf 50.616 Aktien. Er meldet außerdem eine indirekte wirtschaftliche Eigentümerschaft von 363 Aktien, die in einem Profit Sharing Trust gehalten werden. Die Einreichung ist von einem Bevollmächtigten im Namen von Herrn Boudreau unterzeichnet.